Adlah Sukkar, MD
Critical Care Medicine · Annandale, VANPI 1548362791
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 132 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 15.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $905 and has fallen 59.1% since, to $370 in 2025.
Across 132 payments — averaging $26.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Inari Medical, Inc.$556
- GSK$418
- Boehringer Ingelheim$396
- Pulmonx Corporation$352
- AstraZeneca$307
- Electromed, Inc.$253
- plus $1K from 24 others
What the payments were for
- Food & beverage$3,551100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Inari Medical, Inc. | 3 | $556 |
| GSK | 25 | $418 |
| Boehringer Ingelheim | 18 | $396 |
| Pulmonx Corporation | 4 | $352 |
| AstraZeneca | 18 | $307 |
| Electromed, Inc. | 5 | $253 |
| Baxter Healthcare | 4 | $123 |
| Insmed, Inc. | 6 | $117 |
| Sanofi | 6 | $115 |
| Actelion Pharmaceuticals US, Inc. | 4 | $98 |
| Regeneron Healthcare Solutions, Inc. | 3 | $94 |
| Amgen | 4 | $88 |
| Johnson & Johnson | 4 | $66 |
| Mylan Specialty L.p. | 3 | $64 |
| Pfizer | 4 | $60 |
| Philips North America LLC | 3 | $55 |
| Shionogi Inc | 2 | $51 |
| Grifols USA, LLC | 2 | $47 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $34 |
| Novartis | 2 | $32 |
| Genentech USA, Inc. | 2 | $31 |
| Mallinckrodt Hospital Products Inc. | 1 | $29 |
| Alcresta Therapeutics, Inc. | 1 | $29 |
| United Therapeutics Corporation | 1 | $24 |
| Bayer | 1 | $24 |
| Medical Graphics Corporation | 1 | $20 |
| Vapotherm Inc | 1 | $19 |
| Sunovion Pharmaceuticals Inc. | 1 | $16 |
| Merck | 1 | $16 |
| Gilead | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,551 in reported general payments places this provider in the 80th percentile of 174 critical care medicine providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 87 | $106,624 |
| Spiriva RespimatTiotropium Bromide | 63 | $64,284 |
| Breo ElliptaFluticasone/Vilanterol | 53 | $33,146 |
| EliquisApixaban | 28 | $32,265 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 28 | $17,724 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 15 | $14,820 |
| Arnuity ElliptaFluticasone Furoate | 36 | $12,793 |
| SymbicortBudesonide/Formoterol Fumarate | 17 | $9,050 |
| DuleraMometasone/Formoterol | 19 | $7,768 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 28 | $5,602 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 11 | $5,439 |
| Qvar RedihalerBeclomethasone Dipropionate | 17 | $4,487 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 155 | $4,394 |
| Levalbuterol Tartrate HfaLevalbuterol Tartrate | 25 | $1,443 |
| Azithromycin | 78 | $1,313 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta | $418 | $167,383191 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat | $396 | $69,72374 claims |
| PfizerEliquis | $60 | $32,26528 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $307 | $26,77445 claims |
| MerckDulera | $16 | $7,76819 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 174 critical care medicine providers in Virginia.
Other critical care medicine in Annandale
- Matthew WilliamsAnnandale$235K
- Ellen VaugheyAnnandale$6K
- Thieu DoAnnandale$842
- Oksana ShlobinFalls Church$375K
- Sami Abdul JawadFalls Church$193K
- Rajiv MalhotraRichmond$187K
- Thomas BouderWinchester$163K
- Christopher KingFalls Church$131K
- Rohit GoyalFredericksburg$95K
- Robert ThieleCharlottesville$52K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.